Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
Maria J. Sambade(University of North Carolina at Chapel Hill), Carey K. Anders(Duke University), Keith Mikule(Tesaro (United States)), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Jing Wang(Central South University), Kaiming Sun(Tesaro (United States)), Amanda E.D. Van Swearingen(Duke Cancer Institute), Charlene Santos(University of North Carolina at Chapel Hill), Marni B. McClure(University of North Carolina at Chapel Hill)
Cited by 24
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917